智通财经网·2025-08-07 12:49Group 1 - Novo Nordisk's Wegovy and Eli Lilly's Mounjaro saw sales in India double in July compared to June, indicating strong demand for these obesity treatments [1] - Wegovy's sales reached 5,000 units with a revenue of 70 million INR (approximately 797,000 USD), while Mounjaro's sales hit 157,000 units with a revenue of 470 million INR [1] - Novo Nordisk's Q2 sales were 76.857 billion DKK, a 13% year-over-year increase, with a net profit of 26.503 billion DKK, up 32% [2] Group 2 - Eli Lilly reported Q2 revenue of 15.6 billion USD, a year-over-year increase of approximately 38%, but faced challenges with its oral weight loss drug underperforming expectations [2] - Novo Nordisk is advancing its research on Amycretin for weight management and has initiated the REDEFINE11 study to explore CagriSema's potential [2] - As of the latest trading, Novo Nordisk's stock rose by 8% in pre-market, while Eli Lilly's stock fell by 7.8% [3]